Hypermeglycemia Suppresses Calcium Phosphate–Induced Aneurysm Formation Through Inhibition of Macrophage Activation

Teruyoshi Tanaka, PhD; Yuichiro Takei, PhD;* Dai Yamanouchi, MD, PhD

Background—The aim of this study was to elucidate aspects of diabetes mellitus–induced suppression of aneurysm. We hypothesized that high glucose suppresses aneurysm by inhibiting macrophage activation via activation of Nr1h2 (also known as liver X receptor β), recently characterized as a glucose-sensing nuclear receptor.

Methods and Results—Calcium phosphate (CaPO₄)–induced aneurysm formation was significantly suppressed in the arterial wall in type 1 and 2 diabetic mice. A murine macrophage cell line, RAW264.7, was treated with tumor necrosis factor α (TNF-α) plus CaPO₄ and showed a significant increase in matrix metalloproteinase 9 (Mmp9) mRNA and secreted protein expression compared with TNF-α alone. Elevated Mmp9 expression was significantly suppressed by hyperglycemic conditions (15.5 mmol/L glucose) compared with normoglycemic conditions (5.5 mmol/L glucose) or normoglycemic conditions with high osmotic pressure (5.5 mmol/L glucose + 10.0 mmol/L mannitol). Nr1h2 mRNA and protein expression were suppressed by treatment with TNF-α plus CaPO₄ but were restored by hyperglycemic conditions. Activation of Nr1h2 by the antagonist GW3965 during stimulation with TNF-α plus CaPO₄ mimicked hyperglycemic conditions and inhibited Mmp9 upregulation, whereas the deactivation of Nr1h2 by small interfering RNA (siRNA) under hyperglycemic conditions canceled the suppressive effect and restored Mmp9 expression induced by TNF-α plus CaPO₄. Moreover, Nr1h2 activation with GW3965 significantly suppressed CaPO₄–induced aneurysm in mice compared with vehicle-injected control mice.

Conclusions—Our results show that hyperglycemia suppresses macrophage activation and aneurysmal degeneration through the activation of Nr1h2. Although further validation of the underlying pathway is necessary, targeting Nr1h2 is a potential therapeutic approach to treating aneurysm. (J Am Heart Assoc. 2016;5:e003062 doi: 10.1161/JAHA.115.003062)

Key Words: aneurysm • diabetes mellitus • LXRβ • macrophage activation • metalloproteinases • Nr1h2

Aneurysm, although it shares most of the same common risk factors as stenotic arterial disease, including male sex, aging, hypertension, dyslipidemia, and smoking.⁵,⁶

Nr1h1 and Nr1h2 (also known as liver X receptor [LXR] α and β, respectively) were recently characterized as glucose-sensing nuclear receptors, although they have been identified for some time.⁷ There has also been great interest in these

From the Division of Vascular Surgery, Department of Surgery, Wisconsin Institute for Medical Research, University of Wisconsin School of Medicine and Public Health, Madison, WI.

Accompanying Figures S1 and S2 are available at http://jaha.ahajournals.org/content/5/3/e003062/suppl/DC1

*Dr Yuichiro Takei is currently located at the Department of Calcified Tissue Biology, Hiroshima University Institute of Biomedical & Health Sciences, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8553, Japan.

Correspondence to: Dai Yamanouchi, MD, PhD, Division of Vascular Surgery, Department of Surgery, Wisconsin Institute for Medical Research, University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave. 5148, Madison, WI 53705. E-mail: yamano@surgery.wisc.edu

Received December 8, 2015; accepted February 17, 2016.

© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

DOI: 10.1161/JAHA.115.003062
receptors as novel therapeutic targets for inflammatory diseases because they inhibit inflammatory gene expression downstream of signaling mediated by Toll-like receptor 4, interleukin 1b, and tumor necrosis factor α (TNF-α).8,9

Robertson Remen et al10 demonstrated the effect of the Nr1h (LXR) agonist GW3965 in lipopolysaccharide-induced differentiation of bone marrow–derived macrophages into osteoclasts via an Nr1h2-dependent (but not an Nr1h1-dependent) mechanism.

Although there have been several reports regarding the underlying mechanisms of DM suppression of aneurysm, the effects of DM on macrophages and aneurysmal degeneration are still controversial. Macrophage subpopulations identified by CD68, a macrophage marker, were reported to be significantly higher in diabetic versus nondiabetic patients.11 In contrast, Miyama et al12 showed that hyperglycemia attenuates macrophage infiltration in a mouse model of aneurysm induced by porcine pancreatic elastase. In this study, we focused on how high glucose affects macrophage activation and aneurysm formation through Nr1h2.

Materials and Methods

Materials

TNF-α and GW3965 were purchased from Peprotech and Santa Cruz Biotechnology. Streptozotocin (STZ) was purchased from Sigma-Aldrich. All chemicals used in this study were of the highest purity available.

Cell Culture

Murine monocytic RAW264.7 cells were purchased from American Type Culture Collection (Manassas, VA) and maintained in Dulbecco’s modified Eagle’s medium (Mediatech) containing 10% FBS (Mediatech), 100 IU/mL penicillin, and 100 μg/mL streptomycin (Mediatech). For macrophage activation, 5 × 10^5 cells were plated per well in a 6-well plate and maintained in minimal essential medium α (Mediatech) supplemented with 10% charcoal-stripped FBS with antibiotics.

Cell Viability

RAW264.7 cells were cultivated in 96-well plates (4000 cells per well) 1 day before treatment and were cultured with or without TNF-α plus calcium phosphate (CaPO₄), manitol, and high glucose. The cells were combined with MTT solution (50 ng per well) and incubated for 4 hours. Acid isopropanol (0.04 N HCl in isopropanol) and 3% sodium lauryl sulfate were added to dissolve the reduced MTT crystals (formazan) present in the cells. After mixing, the absorbance was measured at 595 nm, with 655 nm as the reference, using a microplate reader.

Mouse Model of Aneurysm and Treatment

C57BL/6 or KK.Cg-Ay/J mice aged 10 weeks were obtained from the Jackson Laboratory (Bar Harbor, ME). The procedures for creating our modified CaCl₂-induced mouse model of aneurysm were described previously.13 We applied the procedure for the infrarenal aorta to the carotid artery in this study. Briefly, 0.5 mol/L CaCl₂-soaked gauze was applied perivascularly for 10 minutes to the carotid artery. The gauze was replaced with PBS-soaked gauze for 5 minutes, and the incised area was sutured. The excess CaCl₂ is converted into CaPO₄, and the crystals act as adjuvants. After 1 to 4 weeks, the mice were sacrificed, and the carotid arteries were collected after fixing by perfusion with 4% paraformaldehyde. The diameter of the artery at the time of the initial surgery and sacrifice was measured with an electronic digital caliper (VWR International). All animal procedures were conducted in accordance with experimental protocols that were approved by the institutional animal care and use committee at the University of Wisconsin, Madison (protocol M02394).

siRNA Transfection

RAW264.7 cells were transfected with either predesigned Nr1h2 siRNA (Invitrogen) or Silencer Negative Control #1 siRNA (Invitrogen) using Lipofectamine RNAiMAX transfection reagent (Invitrogen), according to the manufacturer’s recommendations. Transfected cells (5 × 10^5) were seeded in 6-well plates for mRNA extraction.

Histological and Immunohistochemical Analysis

The murine carotid artery tissues obtained were fixed with 4% paraformaldehyde overnight. The samples were then embedded with OCT compound (Sakura Tissue Tek), frozen, and sectioned at a thickness of 6 μm per section. For histological analysis, the sections were stained with hematoxylin and eosin and observed by light microscopy (Olympus BH-2). Immunofluorescent staining was performed with rat anti-MOMA-2 (ab33451; Abcam) and donkey anti–rat Alexa 488 (Molecular Probes, Invitrogen). TO-PRO-3 stain (Molecular Probes, Invitrogen) was used to identify nuclei. Fluorescent staining was visualized, and digital images were taken on a Nikon A1R Laser Scanning Confocal imaging system with the appropriate argon-beam lasers.

Western Blotting

Protein extraction was performed at 0 to 4°C. Protein from cultured cells and isolated carotid arteries was extracted with a radioimmunoprecipitation assay buffer supplemented with a protease inhibitor cocktail (Cell Signaling Technology). Next,
20-µg samples were separated on 8%, 10%, or 12% polyacrylamide gels in Laemmli sample buffer and transferred electrophoretically onto polyvinylidene difluoride membranes. The membranes were blocked for 1 hour at room temperature in Tris-buffered saline containing 3% skim milk powder. The primary antibodies used for Western blotting included rabbit matrix metalloproteinase 9 (Mmp9; ab38898; Abcam), rabbit Nr1h2 (sc-1001; Santa Cruz Biotechnology), and mouse α-tubulin (sc-23948; Santa Cruz Biotechnology) antibodies. Primary antibodies were detected using a horseradish peroxidase–conjugated secondary antibody and visualized with the enhanced chemiluminescence kit (Thermo Scientific) or SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific).

Quantitative Polymerase Chain Reaction
Total RNA was extracted from RAW264.7 cells using an RNeasy Plus Mini kit (Qiagen), according to the manufacturer’s instructions. Quantitative polymerase chain reaction was performed with SYBR Green dye in a 7500 Fast Real-Time PCR System (ABI). Mouse Gapdh primers for quantitative polymerase chain reaction were purchased from Qiagen (PPM02946E). The sequences of other primers are as follows: Mmp9, F, 5′-CATTCGCGTGGATAAGGAGT-3′, and R, 5′-GTTCACCTCAGTCACCT-3′; Nr1h2, F, 5′-CAGCAGCTCAGGCCGCCGAG-3′, and R, 5′-GCTACGGGTTAAGTGGG-3′. The expression level for each gene was normalized to the Gapdh expression level in the same sample.

Gelatin Zymography
Gelatin zymography was performed using cell culture medium. The medium was separated with 12.5% SDS-PAGE with 1 mg/mL gelatin incorporated into the gel mixture. Following electrophoresis at 4°C, the gel was washed in 2.5% Triton X-100 and incubated at 37°C for 16 hours in 50 mmol/L Tris-HCl (pH 7.4) containing 10 mmol/L CaCl₂ and 0.05% Brij 35. The gels were then stained with 0.5% Coomassie blue in 30% isopropanol and 10% acetic acid for 1 hour and destained in 12.5% isopropanol and 10% acetic acid.

Statistical Analysis
Data are reported as mean±SD. Statistical analysis was performed with GraphPad Prism version 4.00 (GraphPad Software, Inc). Comparisons between groups at a single time point were performed using the Student t test. Multiple comparisons among treatments were performed by 1-way ANOVA, followed by the Tukey range test. For testing 2 samples from the same population (Figures 1A, 1B, 2A, 2B, and 4E), the Wilcoxon rank sum test was used. P values <0.05 were accepted as statistically significant.

Results
Inhibition of CaPO₄-Induced Aneurysm Formation by Hyperglycemia in a Mouse Model of STZ-Induced Type 1 Diabetes
To examine the effect of hyperglycemia on aneurysm formation in type 1 DM, mice were intraperitoneally injected with STZ or control vehicle. After 7 days, aneurysm was induced with CaPO₄ in a surgical procedure. First, we measured body weight and blood glucose levels and confirmed successful induction of DM in the STZ-induced mice (Figure 1A and 1B). We then induced aneurysm and compared the maximum diameter of the artery after 4 weeks. As shown in Figure 1C and 1D, injection of STZ significantly suppressed aneurysm formation, based on the fold increase of the maximum diameter of the artery at the time of the initial surgery and sacrifice (1.8±0.2 versus 1.5±0.2, P<0.05) (Figure 1D). These results suggest that CaPO₄-induced aneurysm is suppressed by STZ-induced type 1 diabetes. Next, we examined whether macrophage accumulation was suppressed by STZ-induced DM in mice. Monocytes and macrophages, marked by MOMA-2, were localized mostly in the adventitia of mice in the CaPO₄-induced aneurysmal model (Figure 1E). The number of monocytes and macrophages was markedly decreased in STZ-induced mice compared with controls.

Inhibition of CaPO₄-Induced Aneurysm Formation by Hyperglycemia in a Mouse Model of KK-Ay Type 2 Diabetes
We examined the effect of type 2 DM on aneurysm formation by using KK-Ay mice, a model of type 2 DM. We first measured blood glucose levels and body weight. Although body weight showed no significant change in the 2 groups (Figure 2A), blood glucose levels were consistently higher in the KK-Ay mice than in the control mice (Figure 2B). We then induced aneurysm with CaPO₄ in both KK-Ay and control wild-type mice. As shown in Figure 2C, aneurysm formation was suppressed in KK-Ay mice compared with control mice. The diameter of the artery (fold increase) in the KK-Ay mice was significantly lower than in the control mice (1.8±0.2 versus 1.6±0.1, P<0.05) (Figure 2D). The numbers of monocytes and macrophages were also decreased in KK-Ay mice compared with controls (Figure 2E). These results suggest that CaPO₄-induced aneurysm formation was suppressed by the presence of type 2 diabetes in KK-Ay mice.
Inhibition of TNF-α and CaPO₄-Induced Macrophage Activation by High-Glucose Treatment

TNF-α is known to be a key inflammatory mediator of aneurysm formation and macrophage activation. ¹⁴⁻¹⁶ We also reported that CaPO₄ crystals, a major component of arterial calcification, play an important role in aneurysm degeneration by inducing apoptosis of smooth muscle cells and macrophage infiltration. ¹³ Consequently, we established an in vitro aneurysm model by stimulating macrophages with TNF-α plus CaPO₄ crystals and used Mmp9 as a marker of classical

Figure 1. Hyperglycemia suppresses CaPO₄-induced aneurysm formation in a mouse model of type 1 diabetes. Male C57BL mice aged 12 weeks were intraperitoneally injected with 150 mg/mL STZ (n=10) or control vehicle (n=11). After 7 days, aneurysm was induced with CaPO₄ in a surgical procedure. Body weight (A) and blood glucose levels (B) were monitored. C, Representative images of carotid arteries stained with hematoxylin and eosin in control and type 1 diabetes model mice. Scale bar, 400 µm. D, The fold increase of carotid artery diameter at 4 weeks after surgery. E, Representative immunohistochemical images for MOMA-2 and TO-PRO-3 in carotid arteries. Scale bar, 30 µm. Values are presented as mean±SD; *P<0.05. CaPO₄ indicates calcium phosphate; STZ, streptozotocin.
macrophage activation. As shown in Figure 3A and 3B, treatment with TNF-α plus CaPO₄ significantly increased Mmp9 mRNA and secreted protein expression compared with TNF-α treatment alone (50.3±3.5 versus 21.0±1.0 and 7.5±1.7 versus 2.7±0.8, respectively, P<0.01), whereas CaPO₄ treatment alone did not affect Mmp9 expression.

Next, RAW264.7 macrophages were treated with hyperglycemic conditions using 15.5 mmol/L glucose (corresponding to 279.2 mg/dL) to mimic DM-induced hyperglycemia. As shown in Figure 3C and 3D, high-glucose treatment significantly attenuated the elevated Mmp9 mRNA and secreted protein expression induced by TNF-α plus CaPO₄ (17.9±2.5
Figure 3. High-glucose treatment suppresses macrophage activation induced by TNF-α plus CaPO₄. A, Mmp9 mRNA expression levels in RAW264.7 cells after stimulation are shown relative to Gapdh expression. RAW264.7 cells were cultured with TNF-α and/or CaPO₄ for 2 days, and mRNA expression in the cell lysates was determined by quantitative polymerase chain reaction. B, Representative Western blot and densitometric analysis of Mmp9 secreted protein expression levels in culture media from RAW264.7 cells treated with TNF-α and/or CaPO₄. The cells were treated with TNF-α and/or CaPO₄ for 5 days, and the culture medium was then analyzed. C, Mmp9 mRNA expression levels in RAW264.7 cells after stimulation are shown relative to Gapdh expression. RAW264.7 cells were cultured for 3 days under N-Glc (5.5 mmol/L glucose) without TNF-α plus CaPO₄ (NT control), N-Glc with TNF-α plus CaPO₄, Man (5.5 mmol/L glucose and 10.5 mmol/L mannitol) and TNF-α plus CaPO₄, and H-Glc (15.5 mmol/L glucose) with TNF-α plus CaPO₄. D, Representative Western blot and densitometric analysis of secreted Mmp9 expression levels in culture media from RAW264.7 cells treated with TNF-α and/or CaPO₄. The cells were treated with NT or TNF-α plus CaPO₄ and N-Glc, Man, or H-Glc for 5 days, and then the culture medium was analyzed. E, Effect of high-glucose treatment on cell viability. The cells were treated with NT or TNF-α plus CaPO₄ and N-Glc, Man, or H-Glc for 2 days, and then the MTT assay was performed. F, MMP9 gelatinolytic activity according to gelatin zymography. The cells were treated with NT or TNF-α plus CaPO₄ under N-Glc, Man, or H-Glc for 5 days, and then the culture medium was analyzed. Values are presented as mean±SD for at least 3 replicates; *P<0.05. **P<0.01. Relative expression levels for Western blotting were quantified using the ImageJ program (National Institutes of Health). CaPO₄ indicates calcium phosphate; H-Glc, hyperglycemic conditions; Man, normoglycemic conditions with high osmotic pressure; Mmp9, matrix metalloproteinase 9; N-Glc, normoglycemic conditions; NT, no treatment; qPCR, quantitative polymerase chain reaction; TNF-α, tumor necrosis factor α.
versus 50.5±9.7 and 3.6±0.5 versus 6.4±0.3, respectively, 
P<0.01), whereas mannitol treatment, as a control for
osmotic pressure, did not significantly affect Mmp9 mRNA or
secreted protein expression. We performed the MTT assay
and confirmed that high-glucose conditions did not affect
cell viability (Figure 3E). To further examine the effect of
high-glucose treatment on Mmp9 activity, gelatin zymogra-
phy was performed. The medium from RAW264.7 cells
treated with high-glucose conditions showed a decrease in
gelatinolytic activity (Figure 3F), suggesting that high glu-
cose suppresses Mmp9 activity induced by TNF-α plus
CaPO₄ in macrophages.

Increased Nr1h2 Expression Levels by High-
Glucose Treatment

To examine the mechanism by which high glucose suppresses
macrophage activation, we next measured Nr1h2 mRNA
expression levels. Treatment with TNF-α and CaPO₄ signif-
cicantly decreased Nr1h2 mRNA expression compared with the
control (0.2±0.04 versus 1.0±0.2, P<0.01) (Figure 4A),
whereas high-glucose treatment significantly restored the
decreased Nr1h2 mRNA expression (0.8±0.4 versus
0.2±0.04, P<0.05). Mannitol treatment showed no significant
change in expression. As shown in Figure 4B, the same trend

Figure 4. High-glucose treatment increased the mRNA (A) and protein (B) expression of Nr1h2. RAW264.7 cells were treated under N-Glc (5.5 mmol/L glucose) without TNF-α plus CaPO₄ (NT control), N-Glc with TNF-α plus CaPO₄, Man (5.5 mmol/L glucose and 10.5 mmol/L
mannitol) and TNF-α plus CaPO₄, and H-Glc (15.5 mmol/L glucose) with TNF-α plus CaPO₄. The cells were cultured for 2 days, and Nr1h2 mRNA (A) and protein (B) expression in the cell lysates was determined by qPCR and Western blotting, respectively. C, Mmp9 mRNA expression
in RAW264.7 cells under TNF-α plus CaPO₄ stimulation with or without GW3965, a synthetic nonsteroidal Nr1h (LXR) agonist, at 0.1 to 1 μmol/
L. D, Knockdown of Nr1h2 mRNA expression by Nr1h2 siRNA. RAW264.7 cells were transfected with either a predesigned Nr1h2 siRNA or
Silencer Negative Control #1. E, Mmp9 mRNA expression levels in RAW264.7 cells after transfection with siRNA. The cells were treated with
control siRNA or Nr1h2 siRNA. After 4-hour transfection, 5 x 10⁵ cells were seeded in 6-well plates. The cells were then treated with NT or TNF-α
plus CaPO₄ under N-Glc, Man, or H-Glc for 2 days. The mRNA expression in the cell lysates was determined by qPCR. Values are presented as
mean±SD for at least 3 replicates; *P<0.05. CaPO₄ indicates calcium phosphate; H-Glc, hyperglycemic conditions; LXRβ, liver X receptor β
(Nr1h2); Man, normoglycemic conditions with high osmotic pressure; Mmp9, matrix metalloproteinase 9; N-Glc, normoglycemic conditions; NT,
no treatment; si, small interfering; TNF-α, tumor necrosis factor α.
was observed in Nr1h2 protein expression. In the high-glucose treatment group, Nr1h2 protein expression was significantly higher than in the normal glucose treatment group, according to densitometric analysis of Western blotting (1.1±0.1 versus 0.9±0.1, P<0.05). Next, to examine the effect of Nr1h2 activation on macrophages, RAW264.7 cells were treated with GW3965, an Nr1h (LXR) agonist. Although GW3965 treatment did not alter Mmp9 mRNA expression in the untreated cells, it dose-dependently suppressed Mmp9 expression induced by TNF-α plus CaPO4 at 0.1 to 1 μmol/L (Figure 4C). The relative expression in the cells treated with 0.5 and 1 μmol/L GW3965 was significantly lower than in the control (51.7±6.4 versus 66.7±3.1 and 40.9±3.0 versus 66.7±3.1, respectively, P<0.05). We also examined the effects of Nr1h2 siRNA on Mmp9 expression induced by TNF-α plus CaPO4. As shown in Figure 4D, Nr1h2 siRNA knocked down Nr1h2 mRNA expression to 44% of control. In the cells treated with the siRNA control, high-glucose treatment significantly suppressed Mmp9 mRNA upregulation by TNF-α plus CaPO4 (52.2±10.7 versus 86.3±2.2, P<0.05) (Figure 4E). In contrast, in the cells treated with Nr1h2 siRNA, the Mmp9 mRNA upregulation induced by TNF-α plus CaPO4 was not suppressed by high-glucose treatment (99.3±11.2 versus 91.3±4.6). These results suggest the involvement of Nr1h2 in the mechanism by which high glucose suppresses Mmp9 expression in macrophages.

Figure 5. Nr1h (LXR) agonist suppresses CaPO4-induced murine aneurysm formation. Mouse model aneurysms were created by the CaPO4-induction method. The mice were divided into 2 groups: the control group (n=6) and the GW3965-administration group (n=6). GW3965 (20 mg/kg), a synthetic nonsteroidal Nr1h (LXR) agonist, or vehicle (PBS) was intraperitoneally injected into mice every day. After 2 weeks, the mice were sacrificed, and the carotid arteries were collected after perfusing with PBS. A, Representative images of mouse CaPO4-induced aneurysms with hematoxylin and eosin staining are shown. Scale bar, 400 μm. B, The fold increase in arterial diameter after 2 weeks was calculated based on the maximum diameter of the artery at the time of the initial surgery and sacrifice. C, Representative immunohistochemical images for MOMA-2 and TO-PRO-3 in carotid arteries. D, Representative Western blot and densitometric analysis of Mmp9 expression in isolated carotids. Values are presented as mean±SD for 3 replicates; *P<0.05. Relative expression levels for Western blotting were quantified using the ImageJ program (National Institutes of Health). CaPO4 indicates calcium phosphate; LXR, liver X receptor; Mmp9, matrix metalloproteinase 9.
Inhibition of Aneurysm Formation by GW3965

Finally, we examined the effects of GW3965 on CaPO₄-induced aneurysm formation in mice. As shown in Figure 5A, administration of GW3965 (20 mg/kg), with the vehicle (PBS) solution as a control, was administered by intraperitoneal injection for 2 weeks, and this suppressed aneurysmal degeneration. When we calculated the fold increase based on the maximum diameter of the artery at the time of the initial surgery and sacrifice, the value for the GW3965-administration group was significantly lower than that for the control group (1.7±0.2 versus 2.0±0.2, P<0.05) (Figure 5B).

The number of monocytes and macrophages stained with MOMA-2 were also markedly decreased by GW3965 administration compared with the control (Figure 5C). Furthermore, GW3965 suppressed Mmp9 protein expression levels in the isolated carotids compared with the control group (0.4±0.1 versus 1.0±0.4, P<0.05) (Figure 5D). These results suggest that GW3965 suppresses aneurysm formation through inhibition of macrophage activation.

Discussion

MMP9 is known as a marker of classical macrophage activation and as contributing to aneurysm formation through the degradation of type IV collagen and matrix. In the present study, we demonstrated that TNF-α plus CaPO₄ robustly increases Mmp9 mRNA expression and protein secretion compared with TNF-α alone in RAW264.7 cells. We previously reported that CaPO₄ contributes to aneurysm formation through the apoptosis of vascular smooth muscle cells with subsequent macrophage infiltration. Consequently, the activation could be the result of enhanced apoptosis and an indirect positive effect of CaPO₄ on classical macrophage activation.

Several studies have reported that there is a reduced risk of aneurysm in DM patients and it is likely that multiple mechanisms underlie this effect. Our current study showed the inhibitory effect of type 1 and 2 DM on murine aneurysm. We suggest that the inhibitory effect is, at least in part, caused by suppression of macrophage activation because an in vitro assay using TNF-α plus CaPO₄ also showed an inhibitory effect of hyperglycemia on macrophage activation. Hyperglycemia, however, shows no migratory activity in RAW264.7 cells (Figure S1) and caspase-3 activity in the MOVAS mouse vascular smooth muscle cell line (Figure S2). Consequently, hyperglycemia suppresses macrophage activation without affecting migratory activity in macrophages and apoptotic activity in vascular smooth muscle cells.

To further investigate the underlying mechanisms by which hyperglycemia suppresses macrophage activation, we focused on the nuclear receptor Nr1h2, which was once categorized as an orphan receptor but later was found to act as a glucose sensor. Interestingly, Nr1h2 expression was suppressed by stimulation with TNF-α plus CaPO₄ under normal glucose conditions but was not affected under high-glucose conditions. Furthermore, activation of Nr1h2 by the agonist GW3965 mimicked the high-glucose effect in macrophages and suppressed Mmp9 expression and secretion. In contrast, deactivation of this receptor by siRNA canceled the suppressive effect of high glucose on Mmp9 mRNA expression and protein secretion. Together with the results showing suppression of macrophage activation and aneurysm in type 1 and 2 diabetic mice and GW3965-treated mice, these results suggest that hyperglycemia suppresses macrophage activation and aneurysm through the activation of Nr1h2.

The remaining challenges include a lack of understanding of the underlying pathway through which Nr1h2 suppresses Mmp9 expression and classical macrophage activation, as mentioned earlier. A possible pathway could be through nuclear factor κB, which is thought to play a pivotal role in TNF-α–induced inflammatory signaling. Joseph et al reported that the activation of Nr1h1 (LXR) decreases inducible nitric oxide synthase and cyclooxygenase 2 expression by antagonizing nuclear factor κB signaling in murine peritoneal macrophages. A previous study also showed that nuclear factor κB contributes to lipopolysaccharide-induced mouse Mmp9 expression in RAW264.7 cells.

Consequently, further research focusing on the relationship between high glucose–induced activation of Nr1h2 and the nuclear factor κB signaling pathway as well as subsequent macrophage activation is warranted.

We used the carotid artery instead of the abdominal aorta for the mouse aneurysm model. Although another group has used the carotid artery as a model for aortic aneurysm, possible physiological differences between these anatomical structures make the carotid artery an imperfect model and is a limitation of this study.

In conclusion, we showed that the inhibitory effect of DM on mouse aneurysm formation depends on suppression of macrophage activation in the arterial wall. An in vitro assay showed inhibitory effects of hyperglycemia on macrophage activation, possibly through Nr1h2 activation. Activation of Nr1h2 by GW3965 suppressed aneurysm formation in mice. Taken together, our results indicate the inhibitory effect of DM on aneurysm through the inhibition of macrophage activation by Nr1h2. Although further research is warranted to elucidate the underlying mechanisms, GW3965 could lead to a novel therapeutic approach to aneurysm.

Sources of Funding

This work was supported by the AHA project (12SDG120024), “The role of osteoclast-like cells in abdominal aortic aneurysm formation.”
Disclosures

None.

References

Hyperglycemia Suppresses Calcium Phosphate–Induced Aneurysm Formation Through Inhibition of Macrophage Activation

Teruyoshi Tanaka, Yuichiro Takei and Dai Yamanouchi

_J Am Heart Assoc._ 2016;5:e003062; originally published March 28, 2016;
doi: 10.1161/JAHA.115.003062

The _Journal of the American Heart Association_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://jaha.ahajournals.org/content/5/3/e003062